Recent industry reports have highlighted past and projected rapid expansion in the DNA diagnostics and genomics markets, driven by liquid biopsies, direct-to-consumer testing, and personalized ...

Illumina, Inc. has announced the immediate availability of a transformative addition to its industry-leading next-generation sequencing portfolio with the launch of the NextSeq 500 System. The new ...

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its first product based on its novel Illumina Complete Long Read technology is now ...

Most biopharma players need access to gene sequencing services. Illumina is facing a handful of headwinds, but it's still the market leader. Bionano Genomics is unproven but expanding quickly. So ...

Illumina, Inc. has announced the broad availability of mRNA-Seq, a new product for full-length, complementary DNA (cDNA) sequencing on the Genome Analyzer. In contrast to tiling and exon arrays, ...

Illumina, Commercial Metals and Newmont stand out as brokers boost ratings amid inflation concerns and shifting economic signals.

Program aims to address key barriers to genomic sequencing in-country SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based ...

The move by the commission is seen as a test of regulators’ efforts to prevent big companies from buying small innovators. By Steve Lohr Steve Lohr first wrote about Illumina’s confrontation with the ...

Proteomics enables the observation of direct cellular function to gain insights on protein-driven disease traits. (Image Credits: Pixabay) Illumina, Inc. on Monday announced that it will present ...

Early customer data reinforces accuracy and flexibility of novel long-read technology, unlocking access to challenging, low DNA input samples "Illumina Complete Long Reads is more convenient than ...